MedTrace Logo

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

NCT07263035 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-04-09

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if increasing the dose of diuretics to achieve a higher urine sodium target produces better clinical results when treating patients hospitalized with acute heart failure when compared to lower urine sodium target and standard of care.

The main questions it aims to answer are:

1. Does targeting a higher urine sodium goal achieve greater natriuresis and diuresis?
2. Does targeting a higher urine sodium goal reduce frequency of hospital readmissions?
3. Does targeting a higher urine sodium goal reduce hospital length of stay?

Researchers will compare natriuresis-guided arms with standard of care to see if targeting higher natriuresis goals improves significantly over current practice.

Participants will submit urine samples at routine intervals after being given diuretics to evaluate urine sodium concentration. If urine sodium is low then diuretic dose will be increased.

Conditions

  • Heart Failure
  • Heart Failure - NYHA II - IV
  • Heart Failure Acute
  • Acute Heart Failure (AHF)

Interventions

DRUG

Furosemide intravenous solution

Diuretics will be titrated to achieve a urine sodium concentration of 50 mmol/L

DRUG

Furosemide intravenous solution

Diuretics will be titrated to achieve a urine sodium concentration of 85 mmol/L

DRUG

Furosemide intravenous solution

Standard of care

Sponsors & Collaborators

  • Lakeland Regional Health Systems, Inc.

    lead OTHER

Principal Investigators

  • Andrew Lurie, DO · Lakeland Regional Hospital

  • Anas Bizanti, MD · Lakeland Regional Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-06-01
Completion
2027-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07263035 on ClinicalTrials.gov